JUMPCAN(SH:600566)2014-08-11 16:00Financial Performance - The company achieved operating revenue of CNY 1,467,449,880.90, representing a 17.32% increase compared to the same period last year[18]. - Net profit attributable to shareholders reached CNY 255,126,071.13, up 29.52% year-on-year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 231,753,846.64, reflecting a 31.03% increase from the previous year[18]. - The basic earnings per share for the period was CNY 0.329, a 2.17% increase compared to the same period last year[17]. - The company reported a net cash flow from operating activities of CNY 282,949,066.00, an increase of 17.57% year-on-year[18]. Assets and Liabilities - The company's total assets increased by 37.70% to CNY 2,774,003,254.11 compared to the end of the previous year[18]. - The net assets attributable to shareholders rose by 76.13% to CNY 2,029,728,021.97[18]. - Total current assets increased to CNY 1,599,040,433.12 from CNY 948,029,100.28, representing a growth of approximately 68.9%[69]. - Total liabilities decreased to CNY 744,275,232.14 from CNY 862,041,504.87, a reduction of about 13.7%[70]. - Owner's equity rose to CNY 2,029,728,021.97 from CNY 1,152,412,711.84, marking an increase of approximately 76.1%[70]. Investment and Capital Structure - The company raised RMB 622,189,239.00 through a non-public offering of 32,430,000 shares, with a net amount after expenses of RMB 589,759,239.00[92]. - The company issued 32,430,000 new shares, increasing the total share capital to 781,454,701 shares[55]. - The largest shareholder, Jichuan Holdings, holds 66.13% of the shares, totaling 516,757,360 shares[59]. - The total number of shareholders at the end of the reporting period was 6,889[59]. Research and Development - The company continues to focus on product innovation and market expansion in the pharmaceutical and health sectors[21]. - The company received 2 invention patents during the reporting period, including a traditional Chinese medicine composition for hemostasis and another for stroke treatment[22]. - The company expanded its product line with new registrations, including Plurilaxin dispersible tablets and protein succinate iron oral solution[22]. Cash Flow - The company reported a net cash flow from financing activities of ¥369,015,707.85, a significant increase from a negative cash flow of ¥31,063,488.85 in the previous year[28]. - Cash flow from operating activities generated a net amount of ¥282,949,066.00, compared to ¥240,662,246.64 in the previous period, reflecting a 17.6% increase[79]. - The ending balance of cash and cash equivalents increased to ¥198,256,506.73, up from ¥66,091,521.65 in the previous period[79]. Corporate Governance and Compliance - The company has no significant litigation, arbitration, or media disputes during the reporting period[45]. - The company has not engaged in any major asset transactions or corporate mergers during the reporting period[47]. - No penalties or administrative actions were reported against the company or its major stakeholders during the reporting period[53]. Future Outlook and Strategy - The company plans to continue focusing on market expansion and innovation while exploring external acquisition opportunities[26]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[75]. Financial Reporting and Accounting Policies - The company does not have any changes in accounting policies or estimates for the reporting period[155]. - The company’s financial report is unaudited as of June 30, 2014, with the financial statements prepared in RMB[68].